



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

10 June 2025  
EMA/119654/2025

## Draft Agenda – 14<sup>th</sup> Industry stakeholder platform on research and development support

3 July 2025, 12:30 – 17:30 (room 2A and TEAMS)

Co-chairs: Michael Berntgen and Iordanis Gravanis

Item	Agenda	Time
1.	Welcome / Introductions <ul style="list-style-type: none"><li>• Overview of the agenda</li><li>• Review of status of follow-up actions from the last platform meeting</li></ul> <i>EMA</i>	10 min
2.	Development support through scientific advice A. Update from EMA on recent developments <ul style="list-style-type: none"><li>• Latest figures on volume and capacity</li><li>• Application of latest guidance update, including scientific advice for paediatric developments</li><li>• Experience with SAWP-CTCG pilots for providing scientific advice</li><li>• Use of discussion meetings to enable scientific dialogue</li></ul> <i>EMA</i> B. Developers' proposals to enable a more agile offering of scientific advice <ul style="list-style-type: none"><li>• Summary of outcome from a recent roundtable dialogue</li><li>• Proposals to translate ideas into concrete activities</li></ul> <i>Industry</i> C. Developers' proposals to enhance the SAWP-CTCG pilots <ul style="list-style-type: none"><li>• Experience with the pilots to-date</li><li>• Reflections on strengthening the use of the new interface</li></ul> <i>Industry</i>	60 min



3.	<p>Horizon scanning activities by different stakeholders</p> <ul style="list-style-type: none"> <li>Methodologies employed by developers</li> <li>Recent EMA activities on horizon scanning</li> </ul> <p>EMA Industry</p>	30 min
4.	<p>Experience with the new features of the PRIME scheme</p> <ul style="list-style-type: none"> <li>Report from the pilot with feedback from developers of PRIME products focusing on expedited scientific advice, development tracker, and submission readiness meetings</li> <li>Additional insights through an industry survey on perceptions and expectations from PRIME</li> <li>Learnings from these surveys and further refinement of this development support offering for unmet medical need products</li> </ul> <p>EMA Industry</p>	45 min
5.	<p>Piloting of the product development coordinator for PRIME products</p> <ul style="list-style-type: none"> <li>Introduction to the concept of the product development coordinator</li> <li>Discussion on expectations and metrics for measuring of value and impact</li> </ul> <p>EMA</p>	20 min
Coffee break		15 min
6.	<p>Focus group to explore opportunities for the use of Real World Data (RWD) and the generation of Real World Evidence (RWE)</p> <ul style="list-style-type: none"> <li>Update on activities and next steps</li> </ul> <p>EMA Industry</p>	15 min
7.	<p>Moving the stepwise Paediatric Investigation Plan (sPIP) concept from pilot to regular operations</p> <p>A. Update from EMA on recent developments</p> <ul style="list-style-type: none"> <li>Final report from the “sPIP pilot”</li> <li>Progress with the preparation of a joint publication on the experience</li> <li>Monitoring and performance indicators to follow-up on sPIP developments</li> </ul> <p>EMA Industry</p>	30 min
8.	<p>Early engagement meetings that foster innovation</p> <p>A. Report from an EMA survey on available tools and platforms (ITF, PTM, SME briefings, QIG)</p> <p>EMA</p>	30 mins

	B. Additional feedback on industry experience with Portfolio and Technology Meetings <i>Industry</i>	
9.	Delivery of the action plan to strengthen qualification of novel methodologies <ul style="list-style-type: none"> <li>Update on the activities under the action plan</li> </ul> <i>EMA</i> <i>Industry</i>	15 min
10.	Establishment of potential alternatives to animal testing in line with the 3Rs principles <ul style="list-style-type: none"> <li>New opportunities for voluntary data submission</li> </ul> <i>EMA</i>	20 min
11.	Summary of follow up items / Close of the meeting <i>EMA</i>	10 min